Stock market announcement archive

Correction: LIFE: Lifecare ASA Q2 2024

August 30, 2024
Reference is made to the Q2 2024 report published by Lifecare ASA (the “Company”) on 27 August 2024. In connection with the uplisting to Euronext Oslo Børs, the Company has conducted new assessments of its financial statements and, in collaboration with its auditor, concluded to recognize the warrants issued in connection with the previously announced […]
Read more

LIFE: Lifecare ASA Q2 2024

August 27, 2024
Bergen, Norway, 27 August 2024: Today, Lifecare ASA (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q2 financial report and operational update. In the second quarter Lifecare continued to build positive momentum towards automatic production by delivering milestones on a continuous basis over a long […]
Read more

Lifecare Q1 2024 Report – From preparations phase to pilot production

May 8, 2024
Bergen, Norway, May 5th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q1 financial report and operational update. Lifecare Q1 report 2024 is available here Lifecare has been delivering milestones on a continuous basis over a long period. The company has […]
Read more

LIFE – Lifecare’s Annual Report 2023

April 9, 2024
Bergen, Norway, April 9th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Annual Report 2023. – The technology development and company progress were fantastic in 2023. We expect nothing less in 2024, in our mission to make life easier for patients […]
Read more

Lifecare Q4 2023 Report – Steady course

February 27, 2024
Bergen, Norway, February 27th, 2024: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q4 financial report and operational update. Lifecare holds steady a course towards the upcoming automated pilot production. The first three quarters of 2023, Lifecare reported on huge achievements both […]
Read more

LIFE: Lifecare Q3 2023 Report

November 14, 2023
Bergen, Norway, November 14th, 2023: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes Q3 financial report and operational update. Lifecare completed Q3 with many important technology and operational achievements. The Company is shifting focus from conducting research and development to focusing on […]
Read more

Lifecare’s Annual Report 2022: Important milestone achievements

March 28, 2023
For Lifecare 2022 was characterized by confirmation of the technology, ClinicalDevelopment Study, and building an organization that makes us even more robustand competent to face upcoming challenges. - Important milestone achievementsnaturally provide a good basis for the ongoing work related to the glucosesensor, CEO Joacim Holter states.- Our organization proved its capacity in full strength […]
Read more

LIFE: Q4 2022 interim report and webcast

February 28, 2023
Bergen, Norway 28 February 2023Today Lifecare publish Q4 2022 interim report. The consolidated group financials show a revenue in Q4 of 5.31 MNOK, compared to1,6 MNOK in Q4 2021. The unaudited interim figures for 2022 show a revenue of20,7 MNOK compared to 1,6 MNOK in 2021. The report is attached to this releaseand are also […]
Read more

Lifecare Q3 2022: All-time high revenue

December 6, 2022
Bergen, Norway 6.12.2022Today Lifecare announces all-time high revenue in their financial reporting forQ3 2022. - We are pleased to see a positive outcome of the investments we havemade. Furthermore, this provides a base for LifecareŽs continued research andproduct development, says CEO Joacim Holter.The consolidated group financials show a revenue of 15,4 MNOK for the first […]
Read more